• Barrichello AP Hospital Paulistano, São Paulo, SP, Brazil
  • Nogueira-Rodrigues A Universidade Federal de Minas Gerais, Brazil
  • Vieira CM Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
  • Melo AC EVA, Grupo Brasileiro de Tumores Ginecológicos, Brazil
  • Paulino E Centro de Oncologia Integrado (Grupo COI), Rio de Janeiro, RJ, Brazil


Endometrial carcinoma is the most prevalent gynecologic malignancy in many countries, with a rising incidence and mortality in the last decades. Despite that, discovery of new therapies has shown little progress in recent years. Currently, immunotherapy is considered the oncologic milestone in the treatment of several tumors, and there is evidence to present a reasonable response in endometrial cancer mainly in a subgroup with immune microenvironment amplified and a high mutation rate. To date, several trials have been conducted exploring the role of Adoptive Cellular Therapy, Bispecific T-Cell Engager antibodies, immune-modulating agents and other Immunotherapy targets in patients with endometrium cancer with promising results. This review focuses on the evolving paradigm of immunotherapy in the treatment of endometrial cancer, describing the biologic basis, the importance of the molecular classification and the main modalities of immunotherapy studied until now. Immunotherapy represents an encouraging therapeutic in the treatment of endometrial cancer. Additional investigation is required to identify immune targets and predictors of response, allowing for the selection of patients most likely to benefit from immunological treatment.

Jun 30, 2017
How to Cite
AP, Barrichello et al. IMMUNOTHERAPY IN ENDOMETRIAL CANCER. International Journal of Drug Research and Technology, [S.l.], v. 7, n. 3, p. 7, june 2017. ISSN 2277-1506. Available at: <>. Date accessed: 19 jan. 2018.
Research Article